1. Pink Sheet
  2. >>Geography
  3. >>North America

Perrigo Relies On New Products For Fiscal Second-Half Boost

 
• By Dan Schiff

Planned launches of generic Claritin-D, Mucinex and Prevacid 24HR are expected to help Perrigo reach 12% to 14% consumer health care growth in fiscal 2012. Opportunities to gain from J&J and Novartis OTC recalls likely are minimal going forward, the private labeler says on its Q2 earnings call.

Perrigo Co. PLC expects its back-end-loaded new product launches will pick up what so far has been a modest fiscal 2012 for the firm’s consumer health care segment.

The private labeler Feb. 7 reported second-quarter OTC sales of $471.3 million, up 9.6%

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America